Status:
UNKNOWN
Early Response to Interferon Combined Short-Term Nucleoside Analogue Therapy in HBeAg(+) Chronic Hepatitis B
Lead Sponsor:
Sun Yat-sen University
Conditions:
Hepatitis B, Chronic
Eligibility:
All Genders
18-55 years
Phase:
NA
Brief Summary
For HBeAg(+) patients, interferon is used for 12 weeks. On 12th week of treatment, If HBV DNA is undetectable (\<1000 copies/ml), interferon is continued alone for one year. If HBV DNA is still positi...
Eligibility Criteria
Inclusion
- HBsAg posive for 6 months
- HBeAg positive, and HBeAb negative
- HBV DNA\>1.0×E5 copies/ml
- ALT\>80 u/L within 3 months
Exclusion
- pregnant women
- conbination infection of HCV, HAV, or HEV
- conbination infection of HIV
- any contraindication of interferon α
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2010
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00860626
Start Date
January 1 2008
End Date
February 1 2010
Last Update
March 12 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Third Affliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 510000